Medications that increase the risk of photosensitivity

by Marianna Rakovitsky, RPh

Oh, Summer! The weather is warm, the sun is shining and it is the time when we try to get outside as much as possible. Summer is my favorite time of the year. I love the beach, days that are filled with light and sunshine,  trips to the orchards and hanging out in the backyard. The sunshine that makes the summer such a …

Read more…

Medications that increase the risk of photosensitivity

How the Massachusetts gift ban hurts primary care doctors

by Kate Atkinson, MD

Six years ago, I organized a group of female healthcare practitioners for a women’s medical journal club. A multidisciplinary team of doctors and NPs from primary care and sub-specialties regularly attended monthly dinners. Invited speakers presented on a variety of topics and over the course of a meeting we exchanged insights while challenging each other on how best to manage our challenging patients.

Our group grew …

Read more…

How the Massachusetts gift ban hurts primary care doctors

The Massachusetts gift ban benefits health insurance companies

by Edison Wong, MD

With the recent proposal to repeal the so-called Massachusetts “gift ban” (more appropriately referred to as the “interaction ban”), I asked myself who stands to gain the most from such bans?

Is it the consumers or patients? Is it the physicians or their practices? Is it the federal or state governments? Nope. Sadly, it is the insurers who gain the most, at the expense of patients.

The …

Read more…

The Massachusetts gift ban benefits health insurance companies

Will Avandia survive the FDA advisory panel?

by Crystal Phend and Emily Walker

Despite hints that the FDA may be leaning toward pulling rosiglitazone (Avandia) from the market, it’s going to be a tough decision for the advisory committee slated to begin meeting on Tuesday, and things could still go either way, leading endocrinologists predict.

“I think the FDA advisory committee is going to struggle with this because none of the data is conclusive,” …

Read more…

Will Avandia survive the FDA advisory panel?

ADVERTISEMENT

54
pages